Who owns ALLO?
Institutional ownership of Allogene Therapeutics Inc. from Form 13F, Q2 2026
209 institutional managers reported holding Allogene Therapeutics Inc. (ALLO) in Form 13F filings for Q2 2026, with 312,662,114 shares worth $652M. The largest reported holder was BlackRock, Inc. Managers that filed both quarters added a net 128,660,152 shares (+69.9%). 33 opened new positions and 28 sold out.
- Funds holding
- 209
- Value held
- $652M
- New / sold out
- 33 / 28
- Net shares, same filers
- +69.9%
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Largest holders of ALLO
| Fund | Value | Share of 13F holdings | Shares | Move |
|---|---|---|---|---|
| BlackRock, Inc. | $62.7M | 9.6% | 30,146,963 | Added |
| Pfizer Inc | $46.9M | 7.0% | 22,032,040 | Unchanged |
| Frazier Life Sciences Management, L.P. | $46.7M | 7.2% | 22,446,668 | Added |
| State Street Corp | $39.6M | 6.1% | 19,025,826 | Added |
| TPG GP A, LLC | $38.9M | 6.0% | 18,716,306 | Unchanged |
| Sio Capital Management, LLC | $27.7M | 4.3% | 13,323,431 | New |
| Primecap Management Co | $27.3M | 4.2% | 13,123,440 | Added |
| Vanguard Capital Management LLC | $25.3M | 3.9% | 12,166,636 | Added |
| FMR LLC | $25.0M | 3.8% | 12,009,043 | Added |
| Citadel Advisors LLC | $21.0M | 3.2% | 10,087,770 | Added |
| Two Sigma Investments, LP | $16.2M | 2.5% | 7,784,348 | Added |
| Geode Capital Management, LLC | $14.7M | 2.3% | 7,049,328 | Added |
| Goldman Sachs Group Inc | $12.8M | 2.0% | 6,148,959 | Added |
| GordonMD Global Investments LP | $11.0M | 1.7% | 5,298,000 | Added |
| Marshall Wace, LLP | $10.6M | 1.6% | 5,095,408 | Added |
| Patient Square Capital LP | $10.5M | 1.6% | 5,050,000 | Added |
| Aberdeen Group plc | $10.4M | 1.6% | 5,001,752 | Added |
| Millennium Management LLC | $10.1M | 1.5% | 4,843,889 | Added |
| D. E. Shaw & Co., Inc. | $9.8M | 1.5% | 4,710,735 | Added |
| Price T Rowe Associates Inc | $9.7M | 1.5% | 4,639,283 | Trimmed |
| Morgan Stanley | $9.4M | 1.4% | 4,509,962 | Added |
| Woodline Partners LP | $9.4M | 1.4% | 4,500,624 | Added |
| Candriam S.C.A. | $9.0M | 1.4% | 4,336,296 | Added |
| Vanguard Portfolio Management LLC | $8.8M | 1.3% | 4,212,078 | Added |
| Renaissance Technologies LLC | $8.0M | 1.2% | 3,834,312 | Added |
Share of 13F holdings is each fund's shares as a share of the 312,662,114 ALLO shares all 13F filers reported, not of shares outstanding.
Biggest buyers in Q2 2026
- Frazier Life Sciences Management, L.P. Added+$38.8M
- Sio Capital Management, LLC New+$27.7M
- BlackRock, Inc. Added+$23.0M
- FMR LLC Added+$21.7M
- State Street Corp Added+$21.6M
- Vanguard Capital Management LLC Added+$10.9M
- Primecap Management Co Added+$9.9M
- GordonMD Global Investments LP Added+$8.0M
- HRT Financial LP Added+$7.5M
- Aberdeen Group plc Added+$7.4M
Biggest sellers in Q2 2026
- MPM Bioimpact LLC Sold out-$5.5M
- Nuveen, LLC Trimmed-$3.5M
- Balyasny Asset Management L.P. Sold out-$2.9M
- Boxer Capital Management, LLC Trimmed-$2.5M
- Price T Rowe Associates Inc Trimmed-$1.5M
- Jane Street Group, LLC Sold out-$1.2M
- Jacobs Levy Equity Management, Inc Trimmed-$1.2M
- AQR Capital Management LLC Trimmed-$995K
- Algert Global LLC Trimmed-$710K
- XTX Topco Ltd Trimmed-$592K
The change in shares since the quarter before, adjusted for stock splits and priced at the Q2 2026 value per share. Funds bought $292M and sold $25.8M; 99 added and 49 trimmed.
Schedule 13D and 13G filings on ALLO
Owners of more than 5% must file within days, so these can be newer than the 13F data.
- 2026-11-10STATE STREET CORP SCHEDULE 13G filed by Allogene Therapeutics Inc.Schedule 13G
- 2026-08-07STATE STREET CORP SCHEDULE 13G filed by Allogene Therapeutics Inc.Schedule 13G
- 2026-02-13Chang David D SCHEDULE 13G filed by Allogene Therapeutics Inc.Schedule 13G
- 2025-07-16CITADEL ADVISORS LLC SCHEDULE 13G filed by Allogene Therapeutics Inc.Schedule 13G
- 2025-05-13Capital World Investors SCHEDULE 13G filed by Allogene Therapeutics Inc.Schedule 13G
- 2025-02-14Lynx1 Capital Management LP SCHEDULE 13G filed by Allogene Therapeutics Inc.Schedule 13G
Questions about ALLO ownership
- Who owns ALLO stock?
- 209 institutional investment managers reported ALLO positions in their Form 13F filings for Q2 2026, holding 312,662,114 shares worth $652M in total. BlackRock, Inc. reported the largest position.
- Are funds buying or selling ALLO?
- In Q2 2026, 33 managers opened new ALLO positions, 99 added, 49 trimmed and 28 sold out. Managers that filed in both quarters added a net 128,660,152 shares.
- How current is this ALLO institutional ownership data?
- It covers holdings as of the end of Q2 2026. Managers have 45 days after the quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
From the SEC's Form 13F data sets for Q2 2026: every 13F holdings report, matched to ALLO by CUSIP. Options are left out. ALLO news and filings · ALLO insider trades · Top funds